What we do

Quantitative imaging plays a key role for personalized medicine. It enables better diagnosis and drug efficacy measurement, while providing the potential to predict clinical evolution and drug efficiency for disease-changing therapies.

Qynapse® innovates in this area by delivering a unique technology for biomarkers analysis and monitoring.

Technology


Quantifying Imaging Biomarkers
Quick. Reliable. Automated.

Our first software QyScore® computes reliable and reproducible measurements and segmentations of brain structures to assist in central nervous system disease diagnosis, monitoring and treatment.

    • Imaging features:

    • White matter lesion load
    • Total brain volume
    • Hippocampal volume
    • Basal ganglia volume
    • Thalamic volume
    • Cerebellar volume
    • Clinical applications:

    • Multiple sclerosis
    • Alzheimer's disease
    • Parkinson's disease
    • Epilepsy
    • Stroke
    • Bipolar disorder
    • Post-traumatic stress disorder

QyScore® comes with an advanced and user-friendly interface, designed to help neuroradiologists and imaging experts perform more robust and precise image analyses.

  • Global and local atrophies
  • Lesion load

Clinical trials

Qynapse® delivers precise, fast and reliable data analyses, leading to the best therapies assessments through the most relevant imaging endpoints and the most accurate selection of patients, for more targeted and successful clinical trials.

Our team provides the following services for effective clinical trials planning and management:

In particular, the results variability is reduced by automated image quantification, along with the implementation of standardized imaging protocols.

Clinical routine

Clinical benefit

  • In the clinical routine, quantifying imaging biomarkers enables:

    • Measurement of clinical progression
    • Measurement of drug efficacy
    • Monitoring of drug adverse effects

    Qynapse® brings valuable insights into the diagnosis of diseases sub-types and into the prognosis of clinical progression, improving patient care.

Integration: a software delivered as a service

Qynapse® can be fully integrated into routine clinical practice through leading RIS/PACS systems, and can be operated with any MRI scan from 1.5T and 3T scanners.

About us

Qynapse® is a medical device company that provides innovative technology to predict clinical outcome and measure drug efficacy of central nervous system diseases (including multiple sclerosis, Alzheimer’s disease and Parkinson's disease).
 
We give neuroimaging experts the opportunity to take their analyses further by automatically quantifying and integrating a wide range of imaging biomarkers with relevant medical data, to support and promote the development of greater evidence-based treatments.
 
Qynapse® is a spin-off company of the French neuro-imaging platform CATI and is headquartered in Paris, France.
 

Management

  • Olivier Courrèges
    CEO
  • Clarisse Longo dos Santos
    Head of clinical development
  • Jean-Baptiste Martini
    Head of software development
 

Partners

We have developed strategic partnerships to deliver state of the art technology and services for imaging biomarkers analysis and monitoring. Our key technology partners and sponsors include:

Careers

Optimal measures. Optimized therapies.
 
Our mission at Qynapse® is to transform the development and clinical management of innovative therapies for central nervous system diseases.
 
Leveraging cutting-edge image analysis and machine learning technology with unmatched clinical expertise, we develop and commercialize medical devices software that help diagnose, predict clinical evolution and measure drug efficacy in an unprecedented way.
 
We are looking for exceptional talents who are ready to make a difference.
 
 
Here are our current job openings:
 
Don't hesitate to contact us at careers[@]qynapse.com if our current open positions do not match your profile.